Novotech CNS USA Appoints Dr Robert Malone to its Washington, DC BioDesk
SYDNEY, Mar 25, 2019 - (ACN Newswire) - Clinical Network Services (CNS) USA, an integrated services group focused on clinical product development and subsidiary of Asia-Pacific specialist CRO Novotech, today announced the appointment of Dr Robert Malone as Principal Consultant in its Washington D.C. office. CNS is headquartered in Australia with offices in New Zealand, the UK and the USA.
|Dr Robert Malone, Principal Consultant at the CNS BioDesk, Washington D.C.|
Dr Malone brings more than 20 years of management and leadership experience in academia, pharmaceuticals and biotechnology, with deep expertise in regulatory and medical strategy for global clinical product development. Dr Malone is an internationally recognised physician and scientist for his work in clinical trials in the areas of vaccines, gene therapy, biodefense and immunology, and specifically as one of the original inventors of DNA vaccination and multiple non-viral gene therapy technologies (RNA and DNA).
Commenting on the new role, Robert said: "I am delighted to join the CNS BioDesk USA consulting team; this is an exciting opportunity to work within a highly professional and experienced group that is dedicated to adding value to clients' early phase programs and their US regulatory strategies."
Russell Neal, CNS Managing Director said: "Dr Malone brings a wealth of industry and consulting experience to our US BioDesk team, and his appointment reflects CNS' ongoing commitment to the continuous growth and evolution of BioDesk to service CNS' international clients as they navigate US and global regulatory strategies."
CNS' BioDesk division is an intelligent global product development and regulatory affairs consultancy specialising in readying products to swiftly enter the clinic or gain marketing approval. It is a uniquely internationally experienced team with particular expertise in the areas of vaccines, oncology, infectious disease as well as cell and gene therapies.
CNS and Novotech, the largest Asia-Pacific-based CRO, merged in late 2018 as part of a mutual mission to expand services to biopharma for early phase product development and clinical research through to later phase regional and global trials.
About Clinical Network Services
Clinical Network Services (CNS) is an integrated services group focused on product development based in Australia with offices in New Zealand, the UK and the USA, which creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials and the marketplace sooner. CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with a committed, highly experienced Australian/New Zealand clinical services and biometrics team. More about CNS and its intelligent development services at www.clinical.net.au
CNS' BioDesk is an expert consulting team offering CMC/manufacturing, toxicology, clinical and regulatory affairs consulting services for readying products to enter clinical trials or marketing approval. The BioDesk team consists of experienced chemists, toxicologists, medical writers, regulatory affairs specialists and experienced clinicians based in Australia, Europe and the USA. BioDesk works closely with clients to design and implement manufacturing operations and non-clinical plans, mindful of commercial timelines and budgets. More about BioDesk services can be found at www.cnsbiodesk.com
About Novotech - https://novotech-cro.com/welcome
Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech's strong Asia Pacific presence includes running clinical trials in all key regional markets. For more, see www.novotech-cro.com.
For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0
Susan Fitzpatrick-Napier, AU: +61 2 8218 2144
USA: +1 415 951 3228, Asia: +65 3159 3427
Copyright ©2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
More Latest Release >>
Fujitsu Launches 14 New Models of Enterprise Notebooks, Tablets and Workstations Optimized for Remote Work
May 26, 2020 11:10 JST
Fujitsu Develops AI-Video Recognition Technology to Promote Hand Washing Etiquette and Hygiene in the Workplace
May 26, 2020 10:34 JST
Mitsubishi Motors Joins OPEN COVID-19 DECLARATION
May 26, 2020 09:34 JST
Tokyo Metropolitan Government to trial 5G Antenna-equipped Smart Poles in Cooperation with Sumitomo Corporation and NEC
May 25, 2020 10:44 JST
Mazda Begins Providing, Virtual Racing Car, Mazda RX-Vision GT3 Concept Online
May 22, 2020 14:26 JST
'e5 Consortium' Established to Promote Zero-Emission Electric Vessel
May 21, 2020 15:34 JST
TOYOTA GAZOO Racing Decides Not to Participate in 2020 Edition of Nurburgring 24 Hours
May 21, 2020 14:19 JST
Fujitsu RunMyProcess Drives Next Phase of Digital Transformation in Business Processes with DigitalSuite ProcessModeler
May 21, 2020 09:00 JST
MHPS Captures Global Gas Turbine Market Share Leadership Again
May 20, 2020 10:09 JST
Hitachi Awarded Contract to Supply, Install 300 Lifts at HDB Blocks in Singapore
May 19, 2020 11:57 JST
DENSO, Global Mobility Service to Support Delivery of COVID-19 Test Kits in Indonesia
May 18, 2020 17:36 JST
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules
May 18, 2020 13:33 JST
Hitachi to Provide $1 Million in Loans through Kiva to Businesses in Need around the Globe, Affected by the Spread of the COVID-19
May 18, 2020 13:24 JST
Toyota's Adjustments to Domestic Production in June 2020 (as of May 15)
May 15, 2020 17:01 JST
Transgene and NEC Demonstrate High Accuracy of AI-based Neoantigen Prediction for the Design of Individualized Cancer Vaccine TG4050
May 15, 2020 14:10 JST
Fujitsu and Accenture Collaboration Accelerates Reliable Blockchain Interoperability
May 15, 2020 10:11 JST
Mazda Releases FY March 2020 Full Year Financial Results
May 14, 2020 17:01 JST
Fujitsu Sets Out the 'Fujitsu Technology and Service Vision 2020'
May 14, 2020 15:53 JST
Notice of Agreement for the Merger through Absorption (Simplified Absorption-type Merger) of a Consolidated Subsidiary of Fujitsu Limited
May 14, 2020 15:46 JST
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting
May 14, 2020 09:22 JST